Pricing Log in Create free account
Saturday 17 October 2026 Export ALGN’s income statement to Excel — free account

Align Technology, Inc.

ALGN Healthcare Medical Instruments & Supplies

Align Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, up 0.90% from fiscal 2024. In the quarter to June 2026, revenue grew 4.32%, EPS fell 12.2% and free cash flow grew 85.8%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.

147.31 2.03 −1.36%
Market cap
$10.6B
P/E
25.6×
Fwd P/E
20.7×
Dividend yield
—
F-score
6/9
Altman Z
4.73
Beneish M
−2.52
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total sells 1.51
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — 1 — — — — — — — —
Insider Ownership 3.94%

Capital & Financial Ratios $m

Market Cap 10,610.00
Revenue 4,139.53
Net Income 413.58
Free Cash Flow 675.57
Net Debt (1,102.59)
Current Ratio 1.40
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 25.57
Fwd P/E 20.70
P/S ratio 2.54
P/B ratio 2.49
Past 5Y EPS Growth (24.09%) (below 0%: weak)
This Y EPS Growth 7.10%
Next Y EPS Growth 10.23%
Next Y revenue growth 2.97%
Next 5Y EPS Growth 8.82%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.3×, against a ten-year median of 6.7×; over the ten years it ranged from 2.0× in 2025 to 17.7× in 2018.
P/E against its own 10 years 11.61%
10-year low 10-year high
P/S against its own 10 years 2.91%
10-year low 10-year high
P/B against its own 10 years 2.25%
10-year low 10-year high
EV/Sales against its own 10 years 2.73%
10-year low 10-year high
EV/FCF against its own 10 years 1.22%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 973 1,044 1,095 1,103
Receivables 903 996 1,102 1,148
Inventory 297 254 226 212
Other — — 28 —
2,447 2,492 2,617 2,663
2023 2024 2025 Q'26
Payables 113 109 121 110
ST’ Debt — — — —
Other — — — —
2,067 2,038 1,920 1,909

Compound Annual Growth %

10y 5y 3y
Sales 16.92% 10.30% 2.61%
Cash Flow 9.56% (2.18%) 1.42%
Earnings 11.04% (25.40%) 4.31%
Book Value 16.92% 4.60% 3.98%

Revenue $m

Mar Jun Sep Dec Year
’26 1,040 1,056 — — —
’25 979 1,012 996 1,048 4,035
’24 997 1,028 978 995 3,999
’23 943 1,002 960 957 3,862
’22 973 970 890 902 3,735
’21 895 1,011 1,016 1,031 3,953
’20 551 352 734 835 2,472
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 151 193 — — —
’25 53 129 189 223 593
’24 29 160 264 286 738
’23 200 252 287 47 786
’22 30 127 266 145 569
’21 227 318 355 273 1,173
’20 10 60 211 381 662
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 120 199 — — —
’25 27 107 169 187 491
’24 19 106 234 263 623
’23 136 193 266 13 608
’22 (57) 51 191 92 277
’21 184 193 231 164 771
’20 (36) 25 190 328 507
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 1.57 1.51 — — —
’25 1.27 1.72 0.78 1.89 5.65
’24 1.39 1.28 1.55 1.39 5.62
’23 1.14 1.46 1.58 1.64 5.81
’22 1.70 1.44 0.93 0.54 4.61
’21 2.51 2.51 2.28 2.40 9.69
’20 19.21 (0.52) 1.76 2.00 22.41
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 57.31 88.56 188.57 169.84 127.88 494.45 172.05 176.34 196.09 122.00

Analyst estimates 2026–2028

Powerpack
High 102.10 266.41 398.88 334.64 543.65 737.45 658.50 413.20 335.40 237.23
People
People Employees 6,060 8,715 11,660 14,530 18,070 22,540 23,165 21,610 20,945 20,290
Revenue/emp, $m 0.18 0.17 0.17 0.17 0.14 0.18 0.16 0.18 0.19 0.20
Income, $m
Income, $m Revenue 1,080 1,473 1,966 2,407 2,472 3,953 3,735 3,862 3,999 4,035
Gross margin, % 75.50 75.81 73.63 72.46 71.33 74.26 70.52 70.08 70.00 67.19
EBT 243 365 467 563 379 1,012 599 641 609 585
EBT margin, % 22.46 24.76 23.73 23.38 15.33 25.61 16.04 16.60 15.23 14.51
Net income 190 231 400 443 1,776 772 362 445 421 410
Depreciation 24 38 55 79 94 109 126 142 145 237
Per share, $
Per share, $ Revenue 13.52 18.40 24.56 30.30 31.39 50.09 47.76 50.54 53.41 55.62
Earnings 2.38 2.89 5.00 5.57 22.55 9.78 4.62 5.82 5.63 5.66
Cash flow 3.10 5.48 6.93 9.41 8.41 14.86 7.27 10.28 9.86 8.18
Capex (0.88) (2.44) (2.79) (1.88) (1.97) (5.08) (3.73) (2.33) (1.54) (1.41)
Free cash flow 2.22 3.03 4.14 7.52 6.44 9.78 3.54 7.96 8.32 6.77
Book value 12.46 14.41 15.65 16.95 41.06 45.91 46.06 47.50 51.44 55.82
Shares, m 80 80 80 79 79 79 78 76 75 73
Valuation, ×
Valuation, × P/E 40.74 77.72 41.89 50.10 23.66 67.20 45.95 46.13 37.10 27.59
P/S 7.17 12.21 8.53 9.21 17.03 13.12 4.44 5.32 3.90 2.81
P/B 7.78 15.58 13.38 16.46 13.01 14.32 4.61 5.66 4.05 2.80
EV/Sales 6.58 11.72 8.15 8.85 16.64 12.82 4.18 5.07 3.64 2.54
EV/FCF 40.11 71.10 48.38 35.63 81.08 65.71 56.35 32.20 23.40 20.85
Cash, $m
Cash, $m Operating cash flow 248 439 555 747 662 1,173 569 786 738 593
Capex (71) (196) (223) (150) (155) (401) (292) (178) (116) (102)
Free cash flow 177 243 331 598 507 771 277 608 623 491
Balance, $m
Balance, $m Working capital 599 658 610 662 524 570 499 380 454 697
Total debt — — — 59 86 126 127 — — —
Net debt (640) (722) (735) (869) (961) (1,171) (1,000) (973) (1,044) (1,095)
Shareholders’ equity 995 1,154 1,253 1,346 3,234 3,623 3,601 3,630 3,852 4,049
Returns, %
Returns, % ROA 14.85 14.55 20.86 19.45 48.45 14.33 6.08 7.40 6.85 6.59
ROIC 43.81 51.07 56.34 71.00 10.65 24.89 15.44 15.13 13.52 11.55
ROE 20.58 21.53 33.25 34.07 77.55 22.52 10.01 12.31 11.26 10.39
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Align Technology, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SOLV Solventum Corporation $15.0B 10.4× 39.0× +2.22% (above 0%: growing) +1.92% (above 0%: growing) +144.07% (above 0%: growing) 58.22% 8.19% Compare
BAX Baxter International Inc. $13.3B — (loss-making) 44.7× +5.34% (above 0%: growing) +33.33% (above 0%: growing) +119.48% (above 0%: growing) 34.86% 7.33% Compare
RGEN Repligen Corporation $11.7B 234× 112× +11.93% (above 0%: growing) −65.38% (below 0%: shrinking) +27.10% (above 0%: growing) 53.91% 6.85% Compare
COO The Cooper Companies, Inc. $10.9B 19.8× 28.7× +0.56% (above 0%: growing) +357.14% (above 0%: growing) +65.96% (above 0%: growing) 66.77% 20.82% Compare
AVTR Avantor, Inc. $10.9B — (loss-making) 25.5× +0.53% (above 0%: growing) −33.33% (below 0%: shrinking) +12.66% (above 0%: growing) 31.73% 7.20% Compare
ALGN Align Technology, Inc. $10.6B 25.6× 20.7× +4.32% (above 0%: growing) −12.21% (below 0%: shrinking) +85.77% (above 0%: growing) 71.71% 14.58%
ATR AptarGroup, Inc. $7.9B 22.2× 21.0× +6.26% (above 0%: growing) −18.34% (below 0%: shrinking) −23.07% (below 0%: shrinking) 35.61% 12.34% Compare
BLCO Bausch + Lomb Corporation $6.0B — (loss-making) — (loss-making) +9.08% (above 0%: growing) n/m +251.85% (above 0%: growing) 62.20% 5.95% Compare
TFX Teleflex Incorporated $5.4B — (loss-making) 45.3× +28.88% (above 0%: growing) −17.33% (below 0%: shrinking) +220.14% (above 0%: growing) 58.16% 12.77% Compare
Median of peers $10.9B 21.0× 39.0× +5.80% −17.33% +92.72% 56.04% 7.76%

All 55 Medical Instruments & Supplies stocks →

ALGN metrics, ten years each

Align Technology, Inc. (ALGN) key facts

  • Concern: Net income was $410.4 million, or $5.66 per share (basic), a net margin of 10.2%.
  • Strength: Align Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, up 0.90% from fiscal 2024.
  • Align Technology, Inc. (ALGN) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, ALGN traded at $147.31, a market capitalization of $10.6 billion.
  • At that price the stock trades at 25.6× trailing-twelve-month earnings and 2.5× sales; its P/E is higher than 12% of its own readings over the past ten years.
  • Return on equity was 10.4% and debt-to-equity 0.00.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 4.73 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Align Technology, Inc. (ALGN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ALGN · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com